

**Extraordinary Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization  
15 March 2021  
Virtual meeting  
Agenda**

**Monday, 15 March 2021**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
11:00	<b>Closed SAGE meeting</b>	Preparation of the session.	30 min.
<b>11:30</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
12:00	<b>Opening and welcome</b>  Welcome: A. Cravioto. SAGE Chair. 5 min.	<b>Opening of the Plenary Meeting</b>	5 min.
12:05	<b>COVID-19 vaccine - part 1</b>  Update on recent developments including on COVAX. K. O'BRIEN. Director Immunization Vaccines and Biologicals (IVB). 10 min.  Introduction and objective setting. H. NOHYNEK. SAGE Member. 5 min.  Vaccine safety and efficacy data emerging on Janssen's Ad26.COV2.S COVID-19 vaccine clinical trials (phase 1-3 trial results). Risk management plans and other implementation considerations. COMPANY PRESENTATION. 25 min.  Questions. 15 min.	<b>FOR RECOMMENDATION</b>  Purpose: Update on vaccine registration, vaccine introduction status and COVAX.  Presentation of clinical data on Ad26.COV2.S vaccine from phase 1, 2 and 3 studies on safety, immunogenicity and efficacy. Outline of ongoing and planned studies.	55 min.
<b>13:00</b>	<b>Break</b>	<b>Break</b>	<b>10 min.</b>
13:10	<b>COVID-19 vaccine – part 2</b>  Assessment of the critical evidence. SAGE working group. 40 min.  Discussion. 40 min.  Presentation of the remaining draft recommendations. H. NOHYNEK. SAGE Member. 30 min.  Discussion. 30 min.	<b>FOR RECOMMENDATION</b>  Presentation of the assessment of the SAGE working group on the available evidences and the strength of evidences on the questions of the evidence to decision tables.  Based on the presented evidences, presentation of draft recommendations on the use of Ad26.COV2.S vaccine against COVID-19.	2h 20 min.
<b>15:30</b>	<b>End of the meeting</b>		